CG Oncology (NASDAQ:CGON) Director Sells $118,075.68 in Stock

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 1,964 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $60.12, for a total value of $118,075.68. Following the completion of the sale, the director owned 654 shares in the company, valued at approximately $39,318.48. This represents a 75.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Mulay also recently made the following trade(s):

• On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The stock was sold at an average price of $73.01, for a total value of $1,138,956.00.

CG Oncology Price Performance

CG Oncology stock opened at $61.08 on Friday. The business has a 50 day simple moving average of $64.43 and a 200 day simple moving average of $57.07. The company has a market capitalization of $5.39 billion, a PE ratio of -26.21 and a beta of 0.31. CG Oncology, Inc. has a one year low of $23.65 and a one year high of $75.50.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The business had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. Equities analysts anticipate that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CGON shares. Royal Bank Of Canada upped their target price on shares of CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. JPMorgan Chase & Co. boosted their price target on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Wolfe Research began coverage on shares of CG Oncology in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock. Wedbush raised their price objective on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Finally, Wall Street Zen lowered shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.73.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of CG Oncology by 11.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after buying an additional 670,770 shares during the period. Wellington Management Group LLP raised its position in shares of CG Oncology by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company’s stock worth $249,111,000 after acquiring an additional 487,011 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of CG Oncology by 116.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock worth $142,961,000 after acquiring an additional 1,854,386 shares during the last quarter. State Street Corp lifted its stake in shares of CG Oncology by 46.4% during the fourth quarter. State Street Corp now owns 2,996,695 shares of the company’s stock valued at $124,423,000 after acquiring an additional 950,028 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in shares of CG Oncology by 15.0% during the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock valued at $56,270,000 after acquiring an additional 281,637 shares during the period. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.